The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2020 | Impact of prior therapies on efficacy of belantamab mafodotin in R/R myeloma

Name: Impact of prior therapies on efficacy of belantamab mafodotin in R/R myeloma
Uploaded: 2020-06-19T00:00:00Z
Duration: 1 min 17 s
Description: Sagar Lonial, MD, of Winship Cancer Institute of Emory University, Atlanta, GA, discusses how the number of prior therapies affects the efficacy of single-agent belantamab mafodotin, an anti-BCMA immunoconjugate, in relapsed or refractory (R/R) multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sagar Lonial • 19 Jun 2020

EHA 2020

Multiple Myeloma Antibodies Belantamab mafodotin

DREAMM-2

Sagar Lonial, MD, of Winship Cancer Institute of Emory University, Atlanta, GA, discusses how the number of prior therapies affects the efficacy of single-agent belantamab mafodotin, an anti-BCMA immunoconjugate, in relapsed or refractory (R/R) multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).